Actavis Standard Transcends Cash Deals, FTC Tells 3rd Circ.

Law360, New York (April 29, 2014, 3:21 PM ET) -- The Federal Trade Commission on Monday urged the Third Circuit to revive a proposed antitrust class action against GlaxoSmithKline LLC and Teva Pharmaceutical Industries Ltd. over a deal to postpone generics of epilepsy drug Lamictal, arguing that cash isn’t the only form of compensation prohibited under a recent U.S. Supreme Court ruling on pay-for-delay agreements.

In an amicus brief filed with the appeals court, the FTC said a district judge got it wrong when he found that the high court's landmark decision in Federal Trade Commission...
To view the full article, register now.